Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2017-02-01 (9 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: TERRANJOU (49380), Maine-et-Loire
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE DU LAYON-MARTIGNE : revenue, balance sheet and financial ratios
PHARMACIE DU LAYON-MARTIGNE is a French company
founded 9 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in TERRANJOU (49380),
this company of category PME
shows in 2025 a net income positive of 191 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE DU LAYON-MARTIGNE (SIREN 824695019)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
191 354 €
183 087 €
183 140 €
53 751 €
76 855 €
50 242 €
-23 932 €
-3 396 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE DU LAYON-MARTIGNE generates positive net income of 191 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
191 354 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 2%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 81%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
2.126%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
80.58%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE DU LAYON-MARTIGNE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
19.429
16.849
14.278
11.41
8.889
6.047
4.055
2.126
Financial autonomy
71.99
75.056
75.841
78.686
79.229
75.851
82.109
80.58
Repayment capacity
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
2.132025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Excellent
In 2025, the debt ratio of PHARMACIE DU LAYON-MARTIGNE (2.13) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
80.58%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Excellent+7 pts over 3 years
In 2025, the financial autonomy of PHARMACIE DU LAYON-MARTIGNE (80.6%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 201.30. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
201.299
Liquidity indicators evolution PHARMACIE DU LAYON-MARTIGNE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
186.834
160.443
174.867
204.208
190.923
209.148
246.499
201.299
Interest coverage
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
201.32025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Good
In 2025, the liquidity ratio of PHARMACIE DU LAYON-MARTIGNE (201.30) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Positioning of PHARMACIE DU LAYON-MARTIGNE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE DU LAYON-MARTIGNE is estimated at
3 039 681 €
(range 2 062 741€ - 4 769 678€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
2062k€3039k€4769k€
3 039 681 €Range: 2 062 741€ - 4 769 678€
NAF 5 année 2025
Valuation method used
Net Income Multiple
191 354 €
×
15.9x
=3 039 681 €
Range: 2 062 742€ - 4 769 678€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE DU LAYON-MARTIGNE with other companies in the same sector:
Frequently asked questions about PHARMACIE DU LAYON-MARTIGNE
What is the revenue of PHARMACIE DU LAYON-MARTIGNE ?
The revenue of PHARMACIE DU LAYON-MARTIGNE is not publicly disclosed (confidential accounts filed with INPI).
Is PHARMACIE DU LAYON-MARTIGNE profitable?
Yes, PHARMACIE DU LAYON-MARTIGNE generated a net profit of 191 k€ in 2025.
Where is the headquarters of PHARMACIE DU LAYON-MARTIGNE ?
The headquarters of PHARMACIE DU LAYON-MARTIGNE is located in TERRANJOU (49380), in the department Maine-et-Loire.
Where to find the tax return of PHARMACIE DU LAYON-MARTIGNE ?
The tax return of PHARMACIE DU LAYON-MARTIGNE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE DU LAYON-MARTIGNE operate?
PHARMACIE DU LAYON-MARTIGNE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart